<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04692103</url>
  </required_header>
  <id_info>
    <org_study_id>RG1007834</org_study_id>
    <secondary_id>10465</secondary_id>
    <nct_id>NCT04692103</nct_id>
  </id_info>
  <brief_title>Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy</brief_title>
  <official_title>Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-targeted Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies use of F-18 16 alpha-fluoroestradiol ([F-18] FES) positron&#xD;
      emission tomography (PET)/computed tomography (CT) in measuring tumor hormone receptor&#xD;
      expression in patients undergoing endocrine-targeted therapy for newly diagnosed breast&#xD;
      cancer or breast cancer that has come back or spread to other places in the body. Comparing&#xD;
      results of diagnostic procedures done before, during, and after hormone therapy may help&#xD;
      measure a patient's response to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and&#xD;
      FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second&#xD;
      FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor&#xD;
      degrader.&#xD;
&#xD;
      After completion of study, patients are followed up for up to 20 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2041</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV), assessed by a one-sample test of the percent Change in FES SUV</measure>
    <time_frame>From time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 1-12 weeks)</time_frame>
    <description>FES uptake will be quantified using lean body mass adjusted SUV (SULmean). The geometric mean will be calculated for up to 3 lesions per patient. Systematic change in FES SULgmean between baseline and a second FES scan measured using a sign test where the median change is zero.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>F-18 16 alpha-fluoroestradiol (FES) uptake</measure>
    <time_frame>From time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 1-12 weeks)</time_frame>
    <description>Quantitative measures of FES uptake for each disease site will be determined by drawing regions-of-interest on lesions to determine maximal FES uptake (SUVmax) per lesion. Up to 10 sites seen on the static torso survey will be quantified. Lesions will be qualitatively determined to be visible or not visible.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients with a threshold of percentage change, or that surpass a targeted follow-up F-18 16 Alpha-fluoroestradiol (FES) Standardized Uptake Value (SUV)</measure>
    <time_frame>From time of first F-18 FES-PET/CT scan to time of second or third F-18 FES-PET/CT scan (approximately 1-12 weeks)</time_frame>
    <description>The number of patients showing a 20% increase in FES uptake (SULgmean or SUVmax) compared to baseline from the first to second or third scan using a 90% Wilson score binomial confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>From start of therapy up to 20 years</time_frame>
    <description>Time to disease progression will be measured as the time from the start of endocrine therapy to the time the patient is first recorded as having disease progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Estrogen Receptor Positive</condition>
  <condition>Primary or Recurrent Breast Carcinoma</condition>
  <condition>Stage IV Breast Cancer AJCC v6 and v7</condition>
  <arm_group>
    <arm_group_label>Diagnostic (F-18 FES PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo F-18 FES PET/CT scan at baseline. Patients also undergo F-18 FES PET/CT and FDG PET/CT between 1-12 weeks after starting therapy, and then 1-12 weeks after the second FES PET/CT scan. Repeat FDG PET may be omitted in patients on selective estrogen receptor degrader.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F-18 16 Alpha-Fluoroestradiol</intervention_name>
    <description>Undergo F-18 FES PET/CT</description>
    <arm_group_label>Diagnostic (F-18 FES PET/CT)</arm_group_label>
    <other_name>F-18 FES</other_name>
    <other_name>FES</other_name>
    <other_name>Fluorine-18 16 alpha-fluoroestradiol</other_name>
    <other_name>Fluoroestradiol F-18</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo F-18 FES PET/CT</description>
    <arm_group_label>Diagnostic (F-18 FES PET/CT)</arm_group_label>
    <other_name>Medical Imaging</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo F-18 FES PET/CT</description>
    <arm_group_label>Diagnostic (F-18 FES PET/CT)</arm_group_label>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>CT scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludeoxyglucose F-18</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Diagnostic (F-18 FES PET/CT)</arm_group_label>
    <other_name>FDG</other_name>
    <other_name>Fluorodeoxyglucose F18</other_name>
    <other_name>18FDG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Diagnostic (F-18 FES PET/CT)</arm_group_label>
    <other_name>Medical Imaging</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo FDG PET/CT</description>
    <arm_group_label>Diagnostic (F-18 FES PET/CT)</arm_group_label>
    <other_name>CAT Scan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Diagnostic (F-18 FES PET/CT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult, non-pregnant patients with biopsy-proven or clinically obvious primary,&#xD;
             recurrent or metastatic breast cancer&#xD;
&#xD;
          -  Breast cancer from ER+ primary that is seen on other imaging tests. Tumor ER&#xD;
             expression must have been confirmed by immunohistocytochemistry of primary tumor or&#xD;
             recurrent disease.&#xD;
&#xD;
          -  At least one site of disease 1.5 cm or greater is needed to meet the spatial&#xD;
             resolution limits of PET imaging.&#xD;
&#xD;
          -  Patients must have been off tamoxifen or other estrogen receptor blocking agents for&#xD;
             at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FES.&#xD;
&#xD;
          -  Patients must be selected for an endocrine targeted therapy regimen for treatment of&#xD;
             their breast cancer by the referring oncologist. Selected treatments may be part of&#xD;
             experimental treatment protocols for which the patient would be separately consented.&#xD;
&#xD;
          -  Patients must be willing to undergo serial imaging procedures.&#xD;
&#xD;
          -  Patients must agree to allow access to clinical records regarding response to&#xD;
             treatment and long term follow up.&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  An inability to lie still for the tests&#xD;
&#xD;
          -  Individuals weighing more than 300 lb. (this is the weight limit of the scanner table)&#xD;
&#xD;
          -  Pregnant or lactating. Women of childbearing potential with either a positive or no&#xD;
             pregnancy test at baseline are excluded.&#xD;
&#xD;
          -  Any other life-threatening illness (e.g. serious, uncontrolled concurrent infection or&#xD;
             clinically significant cardiac disease - congestive heart failure, symptomatic&#xD;
             coronary artery disease, cardiac arrhythmia not well controlled with medication).&#xD;
&#xD;
          -  Use of tamoxifen, faslodex, DES or any other ER blocking agent &lt; 6 weeks or&#xD;
             chemotherapy &lt; 3 weeks prior to imaging scan.&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (fasting glucose &gt; 200 mg/dL)&#xD;
&#xD;
          -  Adult patients who require monitored anesthesia for PET scanning.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hannah Linden</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hannah Linden</last_name>
    <phone>206 606-6710</phone>
    <email>hmlinden@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Linden</last_name>
      <phone>206-606-6710</phone>
      <email>hmlinden@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Hannah Linden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 30, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

